JPH09512707A - 必須領域に外来ポリヌクレオチドを有する組換えポックスウイルス - Google Patents
必須領域に外来ポリヌクレオチドを有する組換えポックスウイルスInfo
- Publication number
- JPH09512707A JPH09512707A JP7528003A JP52800395A JPH09512707A JP H09512707 A JPH09512707 A JP H09512707A JP 7528003 A JP7528003 A JP 7528003A JP 52800395 A JP52800395 A JP 52800395A JP H09512707 A JPH09512707 A JP H09512707A
- Authority
- JP
- Japan
- Prior art keywords
- poxvirus
- defective
- promoter
- virus
- parental
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 46
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 46
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 46
- 230000002950 deficient Effects 0.000 claims abstract description 149
- 241000700605 Viruses Species 0.000 claims abstract description 148
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 124
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 42
- 229960005486 vaccine Drugs 0.000 claims abstract description 25
- 241001465754 Metazoa Species 0.000 claims abstract description 24
- 230000009261 transgenic effect Effects 0.000 claims abstract description 13
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims abstract description 10
- 238000012217 deletion Methods 0.000 claims abstract description 7
- 230000037430 deletion Effects 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 45
- 230000000295 complement effect Effects 0.000 claims description 32
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 29
- 208000007089 vaccinia Diseases 0.000 claims description 29
- 239000003550 marker Substances 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 claims description 7
- 230000007547 defect Effects 0.000 claims description 7
- 102220614572 WD40 repeat-containing protein SMU1_F18R_mutation Human genes 0.000 claims description 6
- 108700026244 Open Reading Frames Proteins 0.000 claims description 4
- 101710172711 Structural protein Proteins 0.000 claims description 4
- 101150106093 gpt gene Proteins 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 101150083809 D10L gene Proteins 0.000 claims description 3
- 101150044623 D13L gene Proteins 0.000 claims description 3
- 101710091045 Envelope protein Proteins 0.000 claims description 3
- 101710188315 Protein X Proteins 0.000 claims description 3
- 101100498120 Vaccinia virus (strain Western Reserve) VACWR118 gene Proteins 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 208000005585 Poxviridae Infections Diseases 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 102100021696 Syncytin-1 Human genes 0.000 claims 2
- 241001310793 Podium Species 0.000 claims 1
- 230000000994 depressogenic effect Effects 0.000 claims 1
- 229940024231 poxvirus vaccine Drugs 0.000 claims 1
- 230000014616 translation Effects 0.000 abstract description 6
- 239000013612 plasmid Substances 0.000 description 136
- 210000004027 cell Anatomy 0.000 description 134
- 238000010276 construction Methods 0.000 description 38
- 239000012634 fragment Substances 0.000 description 38
- 230000014509 gene expression Effects 0.000 description 27
- 239000000047 product Substances 0.000 description 23
- 239000013598 vector Substances 0.000 description 18
- 101150038402 J1R gene Proteins 0.000 description 17
- 101150069325 RAP94 gene Proteins 0.000 description 17
- 101100427600 Rabbit fibroma virus (strain Kasza) UNG gene Proteins 0.000 description 17
- 101150117314 VETFS gene Proteins 0.000 description 17
- 108700039887 Essential Genes Proteins 0.000 description 16
- 210000003501 vero cell Anatomy 0.000 description 16
- 241000588724 Escherichia coli Species 0.000 description 15
- 101100392973 Cowpox virus (strain GRI-90 / Grishak) H4L gene Proteins 0.000 description 13
- 101150011754 I7L gene Proteins 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 230000006798 recombination Effects 0.000 description 12
- 238000005215 recombination Methods 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 241000700618 Vaccinia virus Species 0.000 description 11
- 101100453221 Vaccinia virus (strain Western Reserve) VACWR093 gene Proteins 0.000 description 11
- 238000010367 cloning Methods 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- 230000002238 attenuated effect Effects 0.000 description 10
- 239000013613 expression plasmid Substances 0.000 description 10
- 210000002443 helper t lymphocyte Anatomy 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 108020005029 5' Flanking Region Proteins 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 238000002744 homologous recombination Methods 0.000 description 7
- 230000006801 homologous recombination Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 101150074155 DHFR gene Proteins 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 5
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108020004440 Thymidine kinase Proteins 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108020005065 3' Flanking Region Proteins 0.000 description 4
- 101150087870 A49R gene Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000701867 Enterobacteria phage T7 Species 0.000 description 4
- 241000700662 Fowlpox virus Species 0.000 description 4
- 101150011112 H4L gene Proteins 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 101150105093 PaPS gene Proteins 0.000 description 4
- 241001135910 Phage M13mp18 Species 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 101710159728 Early transcription factor 82 kDa subunit Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000010222 PCR analysis Methods 0.000 description 3
- 101150003725 TK gene Proteins 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 241000700646 Vaccinia virus WR Species 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 101150029559 hph gene Proteins 0.000 description 3
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 3
- 229940097277 hygromycin b Drugs 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 101150066555 lacZ gene Proteins 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 101150068740 C21R gene Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 241000726306 Irus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102220516341 Obscurin-like protein 1_F17R_mutation Human genes 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 101100502116 Vaccinia virus (strain Copenhagen) F17R gene Proteins 0.000 description 2
- 101100226455 Vaccinia virus (strain Western Reserve) VACWR056 gene Proteins 0.000 description 2
- 108010006886 Vitrogen Proteins 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 108010002685 hygromycin-B kinase Proteins 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 229940116736 romycin Drugs 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000010464 virion assembly Effects 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- 101710092702 47 kDa protein Proteins 0.000 description 1
- 101710122462 65 kDa protein Proteins 0.000 description 1
- -1 A8L Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 101710190314 Early transcription factor 70 kDa subunit Proteins 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 241000702188 Enterobacteria phage M1 Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 101150073066 F13L gene Proteins 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 102100029239 Histone-lysine N-methyltransferase, H3 lysine-36 specific Human genes 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 101000822667 Mus musculus Something about silencing protein 10 Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000044547 Nodal Human genes 0.000 description 1
- 108700024442 Nodal Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 101710124239 Poly(A) polymerase Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 102220465562 Putative uncharacterized protein OBSCN-AS1_F13L_mutation Human genes 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 241001504592 Trachurus trachurus Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 101100502046 Vaccinia virus (strain Western Reserve) VACWR052 gene Proteins 0.000 description 1
- 108700002940 Vaccinia virus early transcription factor Proteins 0.000 description 1
- 101100502047 Variola virus (isolate Human/India/Ind3/1967) C17L gene Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000172097 Xiburema virus Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000003161 proteinsynthetic effect Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940064914 retrovir Drugs 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 親ポックスウイルスの必須領域によって付与される機能を欠く欠陥ポック スウイルスであって、プロモーターの転写調節下の外来ポリヌクレオチドを含む 前記欠陥ポックスウイルス。 2. 前記プロモーターが前記欠陥ポックスウイルスの酵素で作動し得る請求項 1に記載の欠陥ポックスウイルス。 3. 前記プロモーターがポックスウイルスプロモーターである請求項1に記載 の欠陥ポックスウイルス。 4. 前記外来ポリヌクレオチドが前記必須領域に挿入されている請求項1に記 載の欠陥ポックスウイルス。 5. 前記必須領域が前記欠陥ポックスウイルスから欠失している請求項1に記 載の欠陥ポックスウイルス。 6. マーカーが前記必須領域を置換している請求項5に記載の欠陥ポックスウ イルス。 7. 前記外来ポリヌクレオチドが前記マーカーに挿入されている請求項6に記 載の欠陥ポックスウイルス。 8. 前記親ポックスウイルスがワクシニアである請求項1に記載の欠陥ポック スウイルス。 9. 前記必須領域がI7L、F18R、D13L、D6R、A8L、J1R、 J3R、H4L、A10L及びA3Lの中から選択した読取り枠である請求項8 に記載の欠陥ポックスウイルス。 10. 前記必須領域が、14キロダルトンエンベロープタンパク質又は25キ ロダルトン構造タンパク質をコードする読取り枠である請求項8に記載の欠陥ポ ックスウイルス。 11. 請求項1から10のいずれか一項に記載の欠陥ポックスウイルスの欠失 機能を補完する能力を有する細胞系。 12. 前記能力が前記欠陥ポックスウイルスの親ポックスウイルスの必須領域 によって付与される請求項11に記載の細胞系。 13. 前記能力が前記欠陥ポックスウイルスの親ポックスウイルスの必須領域 によって付与され、前記必須領域がポックスウイルス感染によって誘導されたプ ロモーターによって調節される請求項12に記載の細胞系。 14. 前記プロモーターがHsp70プロモーターである請求項13に記載の 細胞系。 15. 請求項1から10のいずれか一項に記載の欠陥ポック スウイルスの欠失機能を補完する能力を有するトランスジェニック動物。 16. 前記能力が前記欠陥ポックスウイルスの親ポックスウイルスの必須領域 によって付与される請求項15に記載のトランスジェニック動物。 17. 請求項1から10のいずれか一項に記載の欠陥ポックスウイルスの欠失 機能を補完する能力を有するヘルパーウイルス。 18. 前記能力が前記欠陥ポックスウイルスの親ポックスウイルスの必須領域 によって付与される請求項17に記載のヘルパーウイルス。 19. タンパク質を製造する方法であって、親ポックスウイルスの必須領域に よって付与される機能を欠く欠陥ポックスウイルスを供給するステップを含み、 前記欠陥ポックスウイルスが前記タンパク質をコードする外来ポリヌクレオチド を含み、前記ポリヌクレオチドがプロモーターの転写調節下にある前記方法。 20. 前記プロモーターが前記欠陥ポックスウイルスの酵素で作動し得る請求 項19に記載の方法。 21. 前記プロモーターがポックスウイルスプロモーターである請求項19に 記載の方法。 22. 前記供給ステップを、前記ポリヌクレオチドを前記親ポックスウイルス の必須領域に挿入することによって実施する請求項19に記載の方法。 23. 前記供給ステップを、前記親ポックスウイルスの前記必須領域を前記ポ リヌクレオチドで置換することによって実施する請求項19に記載の方法。 24. 前記供給ステップを、前記親ポックスウイルスの前記必須領域をマーカ ーで置換することによって実施する請求項19に記載の方法。 25. 前記ポリヌクレオチドを前記マーカー内に挿入する請求項24に記載の 方法。 26. 前記ポリヌクレオチドで前記マーカーを置換する請求項24に記載の方 法。 27. 前記マーカーがgpt遺伝子である請求項24に記載の方法。 28. 親ポックスウイルスの必須領域によって付与される機能を欠く欠陥ポッ クスウイルスを含むワクチンであって、前記 欠陥ポックスウイルスが抗原をコードするポリヌクレオチドを含み、前記ポリヌ クレオチドがプロモーターの転写調節下にある前記ワクチン。 29. 前記プロモーターが前記欠陥ポックスウイルスの酵素で作動し得る請求 項28に記載のワクチン。 30. 前記プロモーターがポックスウイルスプロモーターである請求項28に 記載のワクチン。 31. 前記親ポックスウイルスがワクシニアである請求項28に記載のワクチ ン。 32. ワクチンの製造方法であって、親ポックスウイルスの必須領域によって 付与される機能を欠く欠陥ポックスウイルスを供給するステップを含み、前記欠 陥ポックスウイルスが抗原をコードするポリヌクレオチドを含み、前記ポリヌク レオチドがプロモーターの転写調節下にある前記方法。 33. 前記プロモーターが前記欠陥ポックスウイルスの酵素で作動し得る請求 項32に記載のワクチン製造方法。 34. 前記プロモーターがポックスウイルスプロモーターである請求項32に 記載のワクチン製造方法。 35. 前記親ポックスウイルスがワクシニアである請求項 32に記載のワクチン製造方法。 36. プロモーターの転写調節下にある外来ポリヌクレオチドを含む欠陥ポッ クスウイルスであって、前記欠陥ポックスウイルスがその由来源である親ポック スウイルスの必須領域によって付与される機能を欠失している前記欠陥ポックス ウイルス。 37. ワクチンの製造方法であって、プロモーターの転写調節下にある外来ポ リヌクレオチドを含む欠陥ポックスウイルスを供給するステップを含み、前記欠 陥ポックスウイルスがその由来源である親ポックスウイルスの必須領域によって 付与される機能を欠失している前記方法。 38. プロモーターの転写調節下にある外来ポリヌクレオチドを含む欠陥ポッ クスウイルスを含むワクチンであって、前記欠陥ポックスウイルスがその由来源 である親ポックスウイルスの必須領域によって付与される機能を欠失している前 記ワクチン。 39. ワクチンを製造するための請求項1から10のいずれか一項に記載の欠 陥ポックスウイルスの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23539294A | 1994-04-29 | 1994-04-29 | |
US08/235,392 | 1994-04-29 | ||
PCT/EP1995/001629 WO1995030018A2 (en) | 1994-04-29 | 1995-04-28 | Recombinant poxviruses with foreign polynucleotides in essential regions |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09512707A true JPH09512707A (ja) | 1997-12-22 |
JP3911010B2 JP3911010B2 (ja) | 2007-05-09 |
Family
ID=22885307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52800395A Expired - Fee Related JP3911010B2 (ja) | 1994-04-29 | 1995-04-28 | 必須領域に外来ポリヌクレオチドを有する組換えポックスウイルス |
Country Status (10)
Country | Link |
---|---|
US (2) | US5766882A (ja) |
EP (1) | EP0758397B1 (ja) |
JP (1) | JP3911010B2 (ja) |
AT (2) | ATE298370T1 (ja) |
AU (1) | AU694519B2 (ja) |
CA (1) | CA2188447C (ja) |
DE (1) | DE69534289T2 (ja) |
DK (1) | DK0758397T3 (ja) |
ES (1) | ES2243937T3 (ja) |
WO (1) | WO1995030018A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016534755A (ja) * | 2013-11-01 | 2016-11-10 | セメンティス リミテッド | ウイルスベクターの作製 |
JP2019528271A (ja) * | 2016-08-19 | 2019-10-10 | セメンティス リミテッド | ウイルスワクチン |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7374768B1 (en) * | 1990-09-25 | 2008-05-20 | Xenova Research Limited | Viral vaccines |
KR100242671B1 (ko) * | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
DE59712852D1 (de) * | 1996-02-28 | 2007-07-19 | Bayer Healthcare Ag | Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen |
US6428965B1 (en) * | 1997-07-17 | 2002-08-06 | The Johns Hopkins University | Screening assays for the interaction of semaphorins and neuropilins |
US20030158396A1 (en) * | 1997-07-29 | 2003-08-21 | Harold Kleanthous | Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome |
US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
FR2772047B1 (fr) * | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
AT406376B (de) | 1998-01-16 | 2000-04-25 | Immuno Ag | Chimäres poxvirus enthaltend eine retrovirale vektorkomponente |
US6497883B1 (en) | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
ES2170622B1 (es) * | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
US20050196755A1 (en) * | 2000-11-17 | 2005-09-08 | Maurice Zauderer | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
JP4368196B2 (ja) * | 2000-11-17 | 2009-11-18 | ユニバーシティー オブ ロチェスター | 真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法 |
WO2004022729A1 (en) * | 2002-09-05 | 2004-03-18 | Bavarian Nordic A/S | Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions |
US7628980B2 (en) * | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
EE05680B1 (et) | 2000-11-23 | 2013-10-15 | Bavarian Nordic A/S | Muundatud vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ning vaktsiin |
US7097842B2 (en) * | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
WO2002086096A2 (en) * | 2001-01-23 | 2002-10-31 | University Of Rochester Medical Center | Methods of producing or identifying intrabodies in eukaryotic cells |
AU2002255495A1 (en) * | 2001-02-02 | 2002-08-19 | University Of Rochester | Methods of identifying regulator molecules |
CA2344208A1 (en) | 2001-04-30 | 2002-10-30 | Oxford Biomedica (Uk) Limited | Method |
US20030148973A1 (en) * | 2001-05-23 | 2003-08-07 | Peter Emtage | MAGE-A1 peptides for treating or preventing cancer |
US20030113919A1 (en) * | 2001-08-17 | 2003-06-19 | Aventis Pasteur, Ltd. | Immunogenic targets for melanoma |
JP4598398B2 (ja) | 2002-02-01 | 2010-12-15 | オックスフォード バイオメディカ (ユーケー) リミテッド | ウイルスベクター |
AU2003239805B2 (en) * | 2002-04-19 | 2009-09-10 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
US7696406B2 (en) * | 2003-07-03 | 2010-04-13 | Board Of Trustees Operating Michigan State University | Expression of a recombinant transgene |
US20070275010A1 (en) * | 2003-09-18 | 2007-11-29 | Mark Feinberg | Mva Vaccines |
US20050266425A1 (en) * | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
US20080053516A1 (en) * | 2006-08-30 | 2008-03-06 | Richard Allen Hayes | Solar cell modules comprising poly(allyl amine) and poly (vinyl amine)-primed polyester films |
US8202967B2 (en) | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
CN102847148A (zh) | 2007-05-03 | 2013-01-02 | 新加坡科技研究局 | 结合细胞内prl-1多肽或prl-3多肽的抗体 |
WO2010071610A1 (en) | 2008-12-19 | 2010-06-24 | Agency For Science, Technology And Research (A*Star) | Severe chikungunya biomarkers |
KR101787776B1 (ko) | 2009-08-19 | 2017-10-18 | 다우 아그로사이언시즈 엘엘씨 | Aad-1 이벤트 das-40278-9, 관련 트랜스제닉 옥수수 식물주, 및 그의 이벤트-특이적 확인 |
AR078253A1 (es) | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad |
GB201006405D0 (en) | 2010-04-16 | 2010-06-02 | Isis Innovation | Poxvirus expression system |
US20120328649A1 (en) | 2010-09-23 | 2012-12-27 | Baxter Healthcare S.A. | Recombinant Viral Vectors and Methods for Inducing an Immune Response to Yellow Fever Virus |
AR083533A1 (es) | 2010-10-22 | 2013-03-06 | Boehringer Ingelheim Vetmed | Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe |
AR088028A1 (es) | 2011-08-15 | 2014-05-07 | Boehringer Ingelheim Vetmed | Proteinas h5, de h5n1 para un uso medicinal |
WO2013033092A2 (en) | 2011-09-03 | 2013-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Streptococcus suis pilus antigens |
US20130171189A1 (en) * | 2011-10-14 | 2013-07-04 | University Of Connecticut | Inducible and repressible vaccinia viruses with improved safety |
US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
EP2958586B1 (en) | 2013-02-21 | 2018-09-05 | Boehringer Ingelheim Vetmedica GmbH | H5 proteins of h5n1 influenza virus for use as a medicament |
JP6821429B2 (ja) | 2013-09-25 | 2021-01-27 | ゾエティス・サービシーズ・エルエルシー | Pcv2b分岐ワクチン組成物及び使用方法 |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
GB201322574D0 (en) | 2013-12-19 | 2014-02-05 | Equigerminal Sa | Retroviral peptides |
KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
JP6395855B2 (ja) | 2014-04-03 | 2018-09-26 | ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド | ブタ流行性下痢ウイルスワクチン |
DK3198017T3 (da) | 2014-09-26 | 2021-04-12 | Us Health | Virusbaserede ekspressionsvektorer og anvendelser deraf |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
EP3261669B1 (en) | 2015-02-25 | 2022-08-03 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
US10548930B2 (en) | 2015-04-17 | 2020-02-04 | Memorial Sloan Kettering Cancer Center | Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors |
MX2017014700A (es) | 2015-05-20 | 2018-08-15 | Broad Inst Inc | Neoantigenos compartidos. |
TWI750122B (zh) | 2015-06-09 | 2021-12-21 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
DE102015111756A1 (de) * | 2015-07-20 | 2017-01-26 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Rekombinanter Orf-Virus-Vektor |
UA124140C2 (uk) | 2015-08-31 | 2021-07-28 | Бьорінгер Інгельхайм Ветмедіка Гмбх | Пестивірусна вакцина проти вродженого тремору поросят |
JP2018526454A (ja) | 2015-09-16 | 2018-09-13 | ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド | ブタコレラ菌−ネズミチフス菌ワクチン |
CN109152827B (zh) | 2016-02-25 | 2023-07-21 | 纪念斯隆凯特琳癌症中心 | 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途 |
SG11201807051VA (en) | 2016-02-25 | 2018-09-27 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
SG11201900595YA (en) | 2016-08-02 | 2019-02-27 | Vaccinex Inc | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
TW201823467A (zh) | 2016-09-20 | 2018-07-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 犬腺病毒載體 |
TWI817933B (zh) | 2016-09-20 | 2023-10-11 | 德商百靈佳殷格翰維美迪加股份有限公司 | 新穎ehv插入位點orf70 |
NZ751966A (en) | 2016-09-20 | 2023-03-31 | Boehringer Ingelheim Vetmedica Gmbh | New promoters |
WO2018054822A1 (en) | 2016-09-20 | 2018-03-29 | Boehringer Ingelheim Vetmedica Gmbh | New swine influenza vaccine |
MX2019005136A (es) | 2016-11-03 | 2019-06-20 | Boehringer Ingelheim Vetmedica Gmbh | Vacuna contra el parvovirus porcino y el virus del sindrome respiratorio reproductivo porcino y metodos de produccion de esta. |
BR112019009133A2 (pt) | 2016-11-03 | 2019-07-16 | Boehringer Ingelheim Vetmedica Gmbh | vacina contra o parvovírus suíno |
WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
EP3573655A2 (en) | 2017-01-30 | 2019-12-04 | Boehringer Ingelheim Animal Health USA Inc. | Porcine coronavirus vaccines |
US11242509B2 (en) | 2017-05-12 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
CN110869047A (zh) | 2017-07-12 | 2020-03-06 | 勃林格殷格翰动物保健美国有限公司 | 塞内卡病毒a免疫原性组合物及其方法 |
EA202090628A1 (ru) | 2017-09-23 | 2020-11-16 | Бёрингер Ингельхайм Ветмедика Гмбх | Система экспрессии paramyxoviridae |
WO2019092027A1 (en) | 2017-11-09 | 2019-05-16 | Boehringer Ingelheim Vetmedica Gmbh | Sapelovirus immunogenic compositions and uses thereof |
AU2019223768A1 (en) | 2018-02-23 | 2020-08-27 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom |
JP7273840B2 (ja) | 2018-03-19 | 2023-05-15 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | 不活性化ul18および/またはul8を有する新しいehv |
WO2019179966A1 (en) | 2018-03-19 | 2019-09-26 | Boehringer Ingelheim Vetmedica Gmbh | Ehv insertion site ul43 |
JP7162072B2 (ja) | 2018-03-26 | 2022-10-27 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | 免疫原性組成物を製造する方法 |
WO2020058341A1 (en) | 2018-09-20 | 2020-03-26 | Boehringer Ingelheim Vetmedica Gmbh | Intranasal vector vaccine against porcine epidemic diarrhea |
TW202027785A (zh) | 2018-09-20 | 2020-08-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 經修飾之pedv棘蛋白 |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
EP4100420A1 (en) | 2020-02-06 | 2022-12-14 | Boehringer Ingelheim Vetmedica GmbH | Polypeptides useful for detecting anti-rhabdovirus antibodies |
AU2021280261A1 (en) | 2020-05-26 | 2023-01-19 | Dionis Therapeutics, Inc. | Nucleic acid artificial mini-proteome libraries |
US20220160864A1 (en) | 2020-10-05 | 2022-05-26 | Boehringer Ingelheim Animal Health USA Inc. | Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof |
MX2023004006A (es) | 2020-10-05 | 2023-04-26 | Boehringer Ingelheim Vetmedica Gmbh | Proteina fusion util para la vacunacion contra el rotavirus. |
WO2023076733A1 (en) | 2021-11-01 | 2023-05-04 | Dana-Farber Cancer Institute, Inc. | Biologically selected nucleic acid artificial mini-proteome libraries |
GB202117405D0 (en) | 2021-12-02 | 2022-01-19 | Univ London Queen Mary | Peptide |
US20240050555A1 (en) | 2022-04-05 | 2024-02-15 | Boehringer Ingelheim Vetmedica Gmbh | Immunogenic composition useful for vaccination against rotavirus |
WO2024015892A1 (en) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364773A (en) * | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
US4722848A (en) * | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5505941A (en) * | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US5110587A (en) * | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US5338683A (en) * | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US5174993A (en) * | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US5155020A (en) * | 1989-03-08 | 1992-10-13 | Health Research Inc. | Recombinant poxvirus host range selection system |
DE4090351T1 (de) * | 1989-03-08 | 1997-07-24 | Health Research Inc | Rekombinantes Pockenvirus-Wirtsselektionssystem |
US5225336A (en) * | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
GB8907468D0 (en) * | 1989-04-03 | 1989-05-17 | Smith Geoffrey L | Vaccinia vectors,vaccinia genes and expression products thereof |
AU634773B2 (en) * | 1989-05-08 | 1993-03-04 | Basil Arif | Spheroidin dna isolate and recombinant entomopoxvirus expression vectors |
US5204243A (en) * | 1990-02-14 | 1993-04-20 | Health Research Incorporated | Recombinant poxvirus internal cores |
EP0550553B1 (en) * | 1990-09-25 | 2000-07-12 | Cantab Pharmaceuticals Research Limited | Viral defective vaccine produced by transcomplementing cell line |
GB9023352D0 (en) * | 1990-10-26 | 1990-12-05 | Lynxvale Ltd | Vaccinia vectors,vaccinia genes and expression products thereof |
US5863542A (en) * | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
US5843456A (en) * | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
KR100242671B1 (ko) * | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
US5997878A (en) * | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
US5989561A (en) * | 1991-03-07 | 1999-11-23 | Virogenetics Corporation | Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses |
EP1380651A2 (en) * | 1991-08-26 | 2004-01-14 | Baxter Healthcare S.A. | Recombinant fowlpox virus with intact FPV-tk-gene |
DE69333751T2 (de) * | 1992-07-30 | 2005-12-29 | Akzo Nobel N.V. | Nicht-verbreitendes lebendes herpesvirusvakzin |
EP0805854A4 (en) * | 1995-01-13 | 2000-06-07 | Virogenetics Corp | IMMUNOGENIC COMPOSITIONS WHICH RECOMBINANT CONTAINED WEAKENED POX VIRUSES THAT EXPECT AN HTLV ANTIQUE |
-
1995
- 1995-04-28 DK DK95919361T patent/DK0758397T3/da active
- 1995-04-28 EP EP95919361A patent/EP0758397B1/en not_active Revoked
- 1995-04-28 CA CA002188447A patent/CA2188447C/en not_active Expired - Fee Related
- 1995-04-28 AT AT95919361T patent/ATE298370T1/de active
- 1995-04-28 JP JP52800395A patent/JP3911010B2/ja not_active Expired - Fee Related
- 1995-04-28 WO PCT/EP1995/001629 patent/WO1995030018A2/en active IP Right Grant
- 1995-04-28 DE DE69534289T patent/DE69534289T2/de not_active Revoked
- 1995-04-28 AU AU25230/95A patent/AU694519B2/en not_active Ceased
- 1995-04-28 ES ES95919361T patent/ES2243937T3/es not_active Expired - Lifetime
- 1995-05-02 AT AT0075295A patent/AT405292B/de not_active IP Right Cessation
-
1996
- 1996-03-14 US US08/616,133 patent/US5766882A/en not_active Expired - Fee Related
-
1997
- 1997-02-21 US US08/802,985 patent/US5770212A/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016534755A (ja) * | 2013-11-01 | 2016-11-10 | セメンティス リミテッド | ウイルスベクターの作製 |
US10544397B2 (en) | 2013-11-01 | 2020-01-28 | Sementis Limited | Viral vector manufacture |
JP2019528271A (ja) * | 2016-08-19 | 2019-10-10 | セメンティス リミテッド | ウイルスワクチン |
Also Published As
Publication number | Publication date |
---|---|
EP0758397A1 (en) | 1997-02-19 |
JP3911010B2 (ja) | 2007-05-09 |
DE69534289T2 (de) | 2006-04-27 |
ES2243937T3 (es) | 2005-12-01 |
ATA75295A (de) | 1998-11-15 |
AT405292B (de) | 1999-06-25 |
US5770212A (en) | 1998-06-23 |
AU694519B2 (en) | 1998-07-23 |
EP0758397B1 (en) | 2005-06-22 |
CA2188447C (en) | 2002-10-22 |
DK0758397T3 (da) | 2005-10-10 |
WO1995030018A2 (en) | 1995-11-09 |
AU2523095A (en) | 1995-11-29 |
US5766882A (en) | 1998-06-16 |
WO1995030018A3 (en) | 1996-01-04 |
DE69534289D1 (de) | 2005-07-28 |
ATE298370T1 (de) | 2005-07-15 |
CA2188447A1 (en) | 1995-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09512707A (ja) | 必須領域に外来ポリヌクレオチドを有する組換えポックスウイルス | |
JP3504659B2 (ja) | 免疫不全ウイルス組換えポックスウイルスワクチン | |
JP4981231B2 (ja) | レトロウイルスパッケージング細胞での発現のためのコドン最適化 | |
FI113476B (fi) | Menetelmä yhdistelmäretroviruksen valmistamiseksi | |
JP2773833B2 (ja) | 感染性薬剤の供給系 | |
US5766598A (en) | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products | |
US20030133917A1 (en) | T cells specific for target antigens and methods and vaccines based thereon | |
KR20000048511A (ko) | 단백질의 고농도 발현 | |
JP2001514518A (ja) | 発現の向上したベクター並びにその製造および使用方法 | |
US20030013076A1 (en) | Parapoxvirus vectors | |
JPH10503644A (ja) | 新規な内部リボソーム侵入部位、これを含むベクター、および治療への使用 | |
NO310306B1 (no) | Fremgangsmåte for fremstilling av et modifisert chordopoxvirus ved hjelp av direkte molekyl¶r kloning av etmodifisert chordopoxvirusgenom, modifisert chordopoxvirus, DNA-molekyl og anvendelse av et modifisert virus for fremstilling avet rekomb | |
AU1397799A (en) | T cells specific for target antigens and methods and vaccines based thereon | |
US5804196A (en) | Self assembled, defective, nonself-propagating viral particles | |
CA2617830C (en) | Direct molecular cloning of a modified eukaryotic cytoplasmic dna virus genome | |
Moss | Poxvirus Vectors: Mammalian Cytoplasmic-Based Expression Systems | |
EP1183383A1 (en) | Siv-based packaging-deficient vectors | |
GB2254424A (en) | Indicator cells and retroviruses for the detection of gene sequenes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040608 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040901 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050510 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050803 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050916 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051025 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060425 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060718 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060904 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061024 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070116 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070126 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |